Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Raymond Brig

Hematology & Oncology Knoxville, TN Medical Doctor

NPI 1588664627 CMS profile 298752

1400 Dowell Springs Road, Suite 200, Knoxville, TN 37909

Open in the dashboard

General payments

$4,684

150 records reported · program years 2019–2023

Research payments

$67,715

Paid to them · 12 records reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$494,736 paid to institutions, not to them · program years 2019–2022

Through program year 2023, Raymond Brig of Knoxville, TN is reported in the CMS Open Payments database as having received $4,684 across 150 general payments and $67,715 in research payments paid to them. Separately, studies naming them as principal investigator received $494,736 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2023 Research $1,400 1
2022 Research $9,080 4
2021 General $12 1
2021 Research $2,220 4
2020 General $439 30
2020 Research $1,226 1
2019 General $4,233 119
2019 Research $53,789 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raymond Brig
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Raymond Brig were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Raymond Brig Hematology & Oncology median Middle half National median
2019 $4,233 $529 $121–$2,516 $163
2020 $439 $339 $82–$2,213 $114
2021 $12 $263 $49–$1,965 $132
2022 $0 $416 $103–$2,395 $149
2023 $0 $542 $125–$2,646 $160
2024 $0 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Radius Health, Inc. $1,886 8 payments
  2. Genentech USA, Inc. $392 22 payments
  3. Novartis Pharmaceuticals Corporation $362 19 payments
  4. Amgen Inc. $329 14 payments
  5. Celgene Corporation $163 4 payments
  6. AstraZeneca Pharmaceuticals LP $162 8 payments
  7. Lilly USA, LLC $155 6 payments
  8. Merck Sharp & Dohme Corporation $139 4 payments
  9. Pfizer Inc. $111 11 payments
  10. Asd Specialty Healthcare, LLC $103 1 payment
  11. Other $883 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,326 145 payments
  2. Travel and Lodging $1,336 3 payments
  3. Education $22 2 payments
Products named General payments · program years 2019–2023
  1. XGEVA $228 8 payments
  2. Kadcyla $201 12 payments
  3. PIQRAY $178 9 payments
  4. TECENTRIQ $178 15 payments
  5. Revlimid $163 4 payments
  6. VERZENIO $155 6 payments
  7. KEYTRUDA $139 4 payments
  8. Perjeta $130 12 payments
  9. Prolia $122 2 payments
  10. IBRANCE $112 11 payments
  11. Other $2,523 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2023
  1. Eli Lilly and Company $55,015 3 payments
  2. Pfizer Inc. $12,700 9 payments

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record